Recent ABOS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:54:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:51:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:49:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:46:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:41:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:36:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:47:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:35:38 AM
- Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/13/2024 08:00:00 PM
- Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference • GlobeNewswire Inc. • 05/08/2024 09:47:25 PM
- Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease • GlobeNewswire Inc. • 05/08/2024 12:00:00 PM
- Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 08:00:00 PM
- Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
- Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights • GlobeNewswire Inc. • 03/26/2024 11:00:00 AM
- Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024 • GlobeNewswire Inc. • 03/19/2024 08:00:00 PM
- Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days • GlobeNewswire Inc. • 03/12/2024 08:00:00 PM
- Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting • GlobeNewswire Inc. • 03/08/2024 01:50:00 PM
- Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting • GlobeNewswire Inc. • 02/21/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:32:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 10:02:07 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 10:01:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 12:16:51 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM